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Abstract 
Formulation is very important in drug delivery. The wrong formulation can render a drug product 
useless. The amount of preclinical (animal and in vitro) work that must be done before a new drug 
candidate can be tested in humans can be a problem. The cost of these cGxP studies is typically $3-$5 
million. If the wrong drug product formulation is tested, new iterations of the formulation must be 
tested with additional costs. 
Data-driven computational science can help reduce this cost. In the absence of existing human 
exposure, a battery of preclinical tests must be performed in at least two species before FDA will 
permit testing in humans.  However, for many drugs (such as those beginning with natural products) 
there is a history of human exposure. In these cases, computer modeling of a population to determine 
human exposure may be adequate to permit phase 1 studies with a candidate formulation in humans. 
The CDC’s National Health and Nutrition Examination Survey (NHANES) is a program of studies 
designed to assess the health and nutritional status of adults and children in the United States. The 
survey is unique in that it combines interviews and physical examinations including laboratory results.  
The NHANES database can be mined to determine exposure to a food additive, and early human 
formulation testing conducted at levels beneath those to which the US population is ordinarily exposed 
through food. These data can be combined with data mined from international chemical shipments to 
validate an exposure model. This paper describes the data driven formulation testing process using a 
new candidate Ebola treatment that, unlike vaccines, can be used after a person has contracted the 
disease. This drug candidate’s mechanism of action permits it to be potentially used against all strains 
of the virus, a characteristic that vaccines might not share. 
  
Keywords: formulation, toxicology, ICH, FDA, pharmaceutical development. 
1 Introduction 
Data-driven computational science has found many applications in drug design. Molecular data 
are commonly used to design new drug molecules. Engineering process simulations guide the 
development of the Chemistry, Manufacturing, and Controls (CMC) section of Investigational New 
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Drug (IND) applications filed at FDA. Computer simulations can also guide the design of human 
clinical trials.  
Recently, a study of molecular modeling of structural and conformational relationships in tRNA 
complexation with chloroethyl nitrosourea derivatives was published (Agarwal, 2017). These 
derivatives are used as chemotherapeutic agents against cancers including brain tumors, Hodgkin's 
disease, small cell lung cancer, and malignant melanoma.  Molecular modeling has been recently used 
to analyze hydrogen bonding to Thr120 and Thr124 for thiadiazolodiazepine analogs used as 
neuromuscular blocking agents (El-Subbagh, 2017).   Poureshghi et al. have used spectroscopic 
techniques combined with molecular modeling methods to study the interaction between lamotrigine 
and human serum albumin (Poureshghi, 2017) Phenylpicolinamide derivatives have been modeled 
using SURFLEX-DOCK module of the SYBYL package (Zhu, 2016) 
Boehling et al. have published a simulation experiment using the discrete element method to 
study the influence of process parameters including spray rate, number of nozzles, drum rotation rate, 
and drum load on the inter-tablet coating variation (Boehling, Analysis of large-scale tablet coating: 
Modeling, simulation and experiments, 2016). Boehling et al. have also studied the scale up process 
for spray coating computationally. Industrial scale up can be a complicated process and sometimes 
fails (Boehling, 2016b). Sensitivity analyses of a simulated pharmaceutical direct compaction process 
using Sobol indices and based on steady-state gains and the frequency response of a planned 
production plant were conducted by Rehrl et al. (Rehrl, 2017).  The continuous manufacturing of 
artemisinin has been studied by process simulations (Jolliffe, 2016).   
Of the three major applications of simulation in pharmaceutical development, clinical trial 
simulations are perhaps the most challenging. The challenge arises from the need to model the 
behavior of a small group of individual human subjects. A company working to get a single drug to 
market can expect to spend at least $350 million before the medicine is approved for sale. Because so 
many new drug candidates fail, large pharmaceutical companies that are working on dozens of drug 
projects simultaneously spend $5 billion per new drug (Herper, 2013).   
Clinical trial simulations can reduce the risk of conducting clinical trials and thus reduce the 
costs.  Mileham et al. have published on risk modeling for clinical trial patient accrual (Mileham, 
2016).  Banks et al. have conducted simulations of clinical trials with missing data (Banks, 2017). 
Basu used modeling to resolve differences between two recent randomized clinical trials intended to 
measure the benefits and harms of blood pressure treatments in patients with cardiovascular disease 
(Basu, 2017).  Finally, Bayesian approaches are being increasingly applied to design and analysis of 
clinical trials.  Wang et al. took a Bayesian approach to an interim futility analysis of a clinical trial 
(Wang, 2016). 
2 Purpose 
The purpose of this study is to use simulations and modeling in a new way: to obviate the need 
for extensive preclinical formulation and toxicology studies, and to thereby speed a candidate Ebola 
therapeutic to the clinic.   
To achieve this purpose, data from the Centers for Disease Control (CDC) National Health and 
Nutrition Examination Survey (NHANES) are combined with data on shipments from food ingredient 
manufacturers to estimate exposure of the US population through foods to a candidate pharmaceutical 
formulation ingredient, beta cyclodextrin (BCD).  Formulation is important in drug delivery. A poor 
formulation can render a drug product useless. A large amount of preclinical research must be 
performed before a new drug candidate can be tested in humans. The cost of these cGxP studies is 
typically $3-$5 million. If the wrong drug product formulation is tested preclinically, new iterations of 
the formulation must be retested with additional costs.  BSN389 Is a diterpene antibiotic designed for 
treatment of Ebola virus infections. The drug arrests viral replication in the body while antibody 
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therapies are administered to eliminate the virus.  However, the drug is poorly soluble in water, 
reducing circulating blood levels of the drug. The goal of formulation is to increase the solubility and 
bioavailability.   
Data-driven computational science can help reduce the cost. In the absence of existing human 
exposure, a battery of tests involving acute and chronic toxicology, cardiovascular, central nervous 
system, and respiratory safety pharmacology must be performed in at least two species before FDA 
will permit testing in humans.  However, for many compounds (such as those beginning with natural 
products) there is a history of human exposure. In these cases, computer modeling of a population to 
determine human exposure may be adequate to permit phase 0-1 studies with a candidate formulation 
in humans. 
The CDC’s National Health and Nutrition Examination Survey (NHANES) is a set of studies 
designed to evaluate the health and nutritional status of adults and children in the United States. 
NHANES is unique in that it combines interviews and dietary information with physical examinations 
including laboratory results.  The NHANES database can be mined to determine the distribution of 
exposures to a food additive, and early human formulation testing conducted at levels beneath those to 
which the US population is ordinarily exposed through food. These data can be combined with data 
mined from international chemical shipments to validate an exposure model. This paper describes the 
data driven formulation testing process using a new candidate Ebola treatment that, unlike vaccines, 
can be used after a person has contracted the disease. This BSN389’s mechanism of action permits it 
to be potentially used against all strains of the virus, a characteristic that vaccines might not share. 
3 β-Cyclodextrin Uses in Food and Pharmaceuticals 
Cyclodextrins (CDs) are available in three common varieties: α-cyclodextrin, β-cyclodextrin and γ-
cyclodextrin, which are together called the first generation (or parent) cyclodextrins. These 
cyclodextrins are composed of six (α), seven (β) and eight (γ) -(1,4)-linked glycosyl units formed into 
a ring.  This ring-shaped molecule is hydrophilic on the outside (so the CD can dissolve in water) and 
has a nonpolar cavity inside, which provides a hydrophobic environment.  Because of this 
hydrophobic cavity, cyclodextrins are able to form inclusion complexes with a variety of hydrophobic 
guest molecules. The fact that β cyclodextrin is used in both food and pharmaceuticals complicates 
BCD exposure estimates, and means that manufacturers must be careful when adding what seems to 
be a small amount of BCD to a product because that small amount may be enough to drive a consumer 
already consuming BCDs from other sources above the Acceptable Daily Intake limit.   
CDs are well understood from a regulatory point of view, and a monograph for BCD appeared 
decades ago in both the US Pharmacopoeia/National Formulary and the European Pharmacopoeia (Del 
Valle, 2004). 
3.1 β-Cyclodextrin 
The oral LD50 in the rat is greater than 5000 mg/kg, and the i.v. LD50 in the rat is between 450 
and 790 mg/kg.  BCD is less irritating than α-cyclodextrin after i.m. injection.  BCD binds cholesterol 
and only very small amounts (1–2%) are absorbed in the upper intestinal tract after oral 
administration.   
3.2 Applications of β-Cyclodextrin 
In a CD each guest molecule is effectively microencapsulated. This encapsulation is employed to 
produce favorable changes in the chemical and physical properties of the guest molecules, including. 
• Improving the solubility of guest molecule. 
 
 
• Immobilizing very volatile substances. 
• Turning liquid forms into powders. 
• Modifying the chemical reactivity of guest molecules. 
• Stabilizing photosensitive or oxygen-sensitive molecules. 
• Protecting molecules from degradation by microorganisms. 
• Masking of bad color, smell or taste. 
These types of uses of cyclodextrins and CD derivatives motivate their many applications in food 
and pharmaceuticals, and increase the possibility of human exposure. 
3.3 Foods and flavors 
 CDs are used in food preparations for flavor protection or flavor delivery. In foods CDs form 
inclusion complexes with many different types of molecules including lipids, flavors and colors. Most 
natural and artificial flavors are volatile oils or liquids, and complexing them with CDs provides an 
alternative to other encapsulation technologies used for flavor protection. CDs are also employed as 
process aids, e.g., to remove cholesterol from products like milk, butter and eggs. CDs can have a 
texture-improving effect on pastry and on meat products. Other applications include reducing 
bitterness, unpleasant smells and tastes, and stabilizing flavors subjected to long-term storage. 
Emulsions like mayonnaise, margarine or butter creams can be stabilized with α-cyclodextrin. As a 
result, CDs are found in many foods to which consumers are exposed. 
 Cyclodextrins are useful in pharmaceuticals for many of the same reasons that they are useful in 
foods.  For example, the addition of α- or β-cyclodextrin increases the water solubility of poorly 
water-soluble drugs. In some cases improving solubility improves bioavailability, increasing the 
effectiveness of the drug and enabling a reduction in dose.  Cyclodextrins can be used analytically or 
preparatively in the separation of drug stereoisomers by the formation of β-cyclodextrin inclusion 
complexes (Armstrong, 1986).  As a result, CDs are found in pharmaceuticals to which consumers are 
exposed. 
3.4 Assessment of β-Cyclodextrin Use 
 An assessment of the consumption of BCD by the U.S. population resulting from the approved 
uses of BCD was conducted. Estimates for the intake of BCD were based on the approved food uses 
and maximum use level in conjunction with food consumption data included in the National Center for 
Health Statistics’ (NCHS) 2009-2010, 2011-2012, and 2013-2014 National Health and Nutrition 
Examination Surveys (NHANES) (Prevention, 2005) (USDA, 2012); (Bodner-Montville J, 2006). 
Calculations for the mean and 90th percentile intakes were performed for representative approved 
food uses of BCD combined (see Appendix for lists of food codes used). The intakes were reported for 
the following population groups: 
  
•        infants, age 0 to 1 year 
•        toddlers, age 1 to 2 years, 
•        children, ages 2 to 5 years, 
•        children, ages 6 to 12 years, 
•        teenagers, ages 13 to 19 years, 
•        adults, ages 20 years and up, 
•        total population (all age groups combined, excluding ages 0-2 years) 
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4 Food Consumption Survey Data 
4.1 Survey Description 
The most recent National Health and Nutrition Examination Surveys (NHANES) for the years 
2013-2014 are available for public use. NHANES are conducted as a continuous, annual survey, and 
are released in 2-year cycles. In each cycle, approximately 10,000 people across the U.S. completed 
the health examination component of the survey. Any combination of consecutive years of data 
collection is a nationally representative sample of the U.S. population. It is well established that the 
length of a dietary survey affects the estimated consumption of individual users and that short-term 
surveys, such as the typical 1-day dietary survey, overestimate consumption over longer time periods. 
Because two 24-hour dietary recalls administered on 2 non-consecutive days (Day 1 and Day 2) are 
available from the NHANES 2009-2010, 2011-2012, and 2013-2014 surveys, these data were used to 
generate estimates for the current intake analysis. 
 The NHANES provide the most appropriate data for evaluating food-use and food-consumption 
patterns in the United States, containing 2 years of data on individuals selected via stratified 
multistage probability sample of civilian non-institutionalized population of the U.S.  NHANES 
survey data were collected from individuals and households via 24-hour dietary recalls administered 
on 2 non-consecutive days (Day 1 and Day 2) throughout all 4 seasons of the year. Day 1 data were 
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consuming food products containing BCD. Individuals were considered users if they consumed 1 or 
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Of course, every food category in which BCD is approved for use does not necessarily incorporate 
BCD into every product at the maximum approved use level.  As a result, the values in Table 2 are 
corrected using the total amount of BCD consumed in food in the United States during the period of 
the survey.  The correction was derived from US population numbers and market research on the 
global β cyclodextrin industry (Research, 2016).  The US population numbers by year for 2010, 2012, 
and 2014 are 308.11 million , 312.86 million, and 317.68 million, respectively (US population 
numbers, 2017). 
To derive the correction factor the US population number for 2014 was multiplied by the fraction 
of people aged two and up in the US consuming the targeted food codes: 
 317680000 persons x 0.5216  =  1.65702e+008, or 165.702 million BCD consumers 
 971 tons of BCD were consumed in US foods in 2014 (see Figure 1).  This number was converted 
to grams and divided by the number of BCD consumers in the United States to give:  
971000000/165702000 = 5.859 g/consumer/yr 
Dividing the grams per consumer per year by 365 gives grams per consumer per day, or 0.01605.  
To derive the correction factor the maximum g/consumer/day for ages 2+ in the NHANES table is 
divided by the actual g/day, 0.5617/0.01605 = 35.0.  The estimated maximum exposures provided by 
the 2013-2014 NHANES were divided by 35 to get estimated actual exposures in Table 2. 
 
 
Figure 1.  Annual US β cyclodextrin consumption by year (metric tons) 
  
BCD exposure from foods is forecast to increase in the near future.  There is a correlation between 
BCD total consumption and exposure estimated from NHANES.  Linear modeling of the NHANES 
data predicts exposure will reach 19 mg by 2020 in the age 2 and up group (see Figure 2). 
 
 
 
Figure 2.  The mass of BCD consumed by users in the US is forecast to increase to 19 
mg/person/day in the age 2 and up group by the year 2020.  
  
Much of the increased exposure to BCD seems to come from an increasing number of food codes 
in categories permitted to incorporate BCD.  Figure 3 shows the number of food codes increasing 
through 2020, which is also correlated to the amount of BCD consumed. 
 
Figure 3.  Every year more food codes are added to categories of foods permitted to incorporate 
BCD.  By 2020 nearly 600 food codes containing BCD may be listed in the FNDDS. 
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6 Conclusions 
  
In summary, 52.2% of the total U.S. population of 2+ years was identified as consumers of BCD 
from the approved food uses. The mean intakes of BCD by the all BCD consumers (“all-user”) from 
all approved food uses were estimated to be 16 mg/person/day or 0.2 mg/kg body weight/day. The 
heavy consumer (90th percentile all-user) intakes of BCD from all approved food-uses were estimated 
to be 36.3 mg/person/day or 0.5 mg/kg body weight/day.  The initial human clinical studies of 
BSN389 will use 1.5 µg of BCD. This is four orders of magnitude less than the expected daily intake 
from food uses, and far less than the amount required to take the average consumer from the 50th to 
the 90th percentile.  For this reason, use of BCD in the BSN 389 formulation is an insignificant 
addition to daily intake and should be safe for subjects in the trial. 
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